The results of a study presented at the Annual European Congress of Rheumatology (EULAR) 2017 press conference showed that, in postmenopausal women with osteoporosis, 12 months treatment with romosozumab was associated with rapid and large reductions in their risk of a vertebral fracture compared to placebo.
Queensland researchers are launching a world-first clinical trial aimed at improving recovery from spinal cord injuries.In the study, led by The University of Queensland and The Princess Alexandra (PA) Hospital, a new anti-inflammatory drug will be given to participants within hours of spinal trauma in an effort to minimise tissue damage.
Spinal cord patients also are at higher risk for cardiovascular disease; pneumonia; life-threatening blood clots; bladder, bowel and sexual dysfunction; constipation and other gastrointestinal problems; pressure ulcers; and chronic pain, according to a report published in the journal Current Neurology and Neuroscience Reports.
A new study reports that PJK risk following lumbar spinal fusion depends on the level of the spine fused. Specifically, the authors – who include members of the International Spine Study Group (ISSG) from multiple academic centers – found that fusing the lower portion of lumbar spine results in a decreased risk of PJK.
A new therapy to treat spinal cord injuries in people who have lost all motor and sensory function below the injury site shows additional motor function improvement at 6-months and 9-months following treatment with 10 million AST-OPC1. The positive efficacy results from an ongoing research study were announced on Jan. 24 in a conference held by Asterias Biotherapeutics, Inc., the biotechnology company that manufactures AST-OPC1.